List of Xuriden drug patents

Xuriden is owned by Wellstat Therap.

Xuriden contains Uridine Triacetate.

Xuriden has a total of 1 drug patent out of which 0 drug patents have expired.

Xuriden was authorised for market use on 04 September, 2015.

Xuriden is available in granule;oral dosage forms.

The generics of Xuriden are possible to be released after 10 July, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6258795 WELLSTAT THERAP Acylated uridine and cytidine and uses thereof
Jul, 2023

(3 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 4, 2022

Drugs and Companies using URIDINE TRIACETATE ingredient

Market Authorisation Date: 04 September, 2015

Treatment: NA


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic